Table 2.

Univariate analysis of risk factors for overall survival among 580 patients with SM

Variables	All patients univariate P (n = 580)	ISM univariate P (n = 291)	Advanced SM univariate P (n = 289)
Median age	<.001	<.001	<.001
Age >60 y	<.001	<.001	<.001
Males	<.001	.4	.17
Anemia sex adjusted	<.001	<.001	<.001
n eval = 574		n eval = 285
Leukocyte count	<.001	.3	.03
n eval = 573		n eval = 284
Platelet count	<.001	.4	<.001
n eval = 567		n eval = 280	n eval = 287
Platelet count <150 × 109/L	<.001	.08	<.001
n eval = 567		n eval = 280	n eval = 287
Urticaria pigmentosa	<.001	.7	<.001
n eval = 577		n eval = 288
Mast cell mediator symptoms	<.001	.009	.68
n eval = 349		n eval = 153	n eval = 196
Palpable hepatomegaly	<.001	.03	.01
n eval = 579			n eval = 288
Palpable splenomegaly	<.001	.006	<.001
n eval = 578		n eval = 290	n eval = 288
Serum albumin	<.001	.4	<.001
n eval = 389		n eval = 157	n eval = 232
Serum albumin <3.5 g/dL	<.001	.2	.01
n eval = 389		n eval = 157	n eval = 232
Serum ALP	<.001	<.001	<.001
n eval = 547		n eval = 269	n eval = 278
Serum ALP > UNL	<.001	.001	<.001
n eval = 547		n eval = 269	n eval = 278
KITD816V	.4	.1	.16
n eval = 357		n eval = 172	n eval = 185
ASXL1 mutated	<.001	No adverse mutations	<.001
n eval = 150			n eval = 107
RUNX1 mutated	.03	No adverse mutations	.05
n eval = 150			n eval = 107
NRAS mutated	.002	No adverse mutations	<.001
n eval = 150			n eval = 107
Adverse mutations	<.001	No adverse mutations	<.001
n eval = 150			n eval = 107
Abnormal karyotype	<.001	.3	<.001
n eval = 53		n eval = 8	n eval = 45

Bold indicates statistical significance (P < .05).